Document is current

Article History

Received: 3 January 2023

Revised: 7 June 2023

Accepted: 20 June 2023

First Online: 4 July 2023

Competing interests

: All authors have read the journal’s authorship agreement and policy on disclosure of potential conflicts of interest and report the following conflict of interests: NH: Employment: OncoLab Diagnostics GmbH; Patents, Royalties, Other Intellectual Property: European Patent Application No. 21197391.2, titled “METHOD OF DETERMINING TUMOR-ASSOCIATED PROTEIN AGGREGATES”; Travel, Accommodations, Expenses: OncoLab Diagnostics GmbH; JS: Consulting for: Eisai, F. Hoffmann-La Roche Ltd, Genmab, GSK, Karyopharm, MSD, Novocure, Novartis, AstraZeneca, Clovis; Grant/Corporate Sponsored Research: Amgen, F. Hoffmann-La Roche; Accommodations, travel expenses: MSD, Tesaro, AstraZeneca, GSK F. Hoffmann-La Roche; EIB: Advisory Board, Steering Committees: AstraZeneca, Clovis, GSK-Tesaro, MSD, EISAI, Roche; Travel, Accommodations, Expenses: AstraZeneca, Clovis, Roche, Tesaro; Research Funding: AstraZeneca, Bayer, GSK, MSD-Merck, Roche Diagnostics; IV: Consulting for: Agenus, Aksebio, AstraZeneca, Bristol Myers Squibb (2021), Deciphera Pharmaceuticals, Eisai, Elevar Therapeutics, F. Hoffmann-La Roche Ltd, Genmab, GSK, Immunogen Inc., Jazzpharma, Karyopharm, Mersana, MSD, Novocure, Novartis, Oncoinvent AS, Seagen, Sotio a.s., Verastem Oncology, Zentalis; Contracted Research (via KU Leuven): Oncoinvent AS (2019-20); Grant/Corporate Sponsored Research: Amgen, F. Hoffmann-La Roche; Accommodations, travel expenses: Amgen, MSD, Tesaro, AstraZeneca, Karyopharm, F. Hoffmann-La Roche; TVG: Consulting for: AstraZeneca, Eisai Europe, OncXerna Therapeutics, MSD/Merck, GSK; Grant/Corporate Sponsored Research: Amgen, Roche; Accommodations, travel expenses: Immunogen, MSD, AstraZeneca, PharmaMar; SM: Research support, advisory board, honoraria and travel expenses: AbbVie, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Medac, MSD, Novartis, Olympus, PharmaMar, Pfizer, Roche, Sensor Kinesis, Teva, Tesaro; CG: Consulting for: AstraZeneca, Celgene, MSD, PharmaMar, Roche, GSK, Vifor Pharma, Clovis; Grant/Corporate Sponsored Research: Meda Pharma, Roche Diagnostics, AstraZeneca; Accommodations, travel expenses: AstraZeneca, PharmaMar, Roche, GSK; NC: Consulting/Advisory: Seagen, Akesobio, Ensai, GSK, AstraZeneca, Mersana, Seattle Genetics, eTheRNA immunotherapies NV; Travel Expenses: Roche, Genmab, Amgen; Educational fees: MSD, Medscape Oncology, TouchIME; RZ: Employment: OncoLab Diagnostics GmbH; Leadership: OncoLab Diagnostics GmbH; Stock and Other Ownership Interests: OncoLab Diagnostics GmbH; Patents, Royalties, Other Intellectual Property: European Patent Application No. 21197391.2, titled “METHOD OF DETERMINING TUMOR-ASSOCIATED PROTEIN AGGREGATES”; Patents at OncoLab Diagnostics GmbH. The other authors have no additional financial interests.